U.S. patent application number 09/516981 was filed with the patent office on 2002-03-14 for pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound.
Invention is credited to Curaudeau, Alain H, Dunwiddie, Christopher T, Leadley, Robert J, Perrone, Mark H, Uzan, Andre.
Application Number | 20020032214 09/516981 |
Document ID | / |
Family ID | 21861879 |
Filed Date | 2002-03-14 |
United States Patent
Application |
20020032214 |
Kind Code |
A1 |
Uzan, Andre ; et
al. |
March 14, 2002 |
Pharmaceutical composition comprising a compound having anti-xa
activity and a platelet aggregation antagonist compound
Abstract
The invention is also directed to pharmaceutical composition
comprising a compound having anti-Xa activity, a platelet
aggregation antagonist compound and a pharmaceutically acceptable
carrier. The invention is also directed to a method of treating or
preventing a thrombogenic condition associated with a thrombosis
related ischemic disorder in a patient comprising administering to
said patient pharmaceutically effective amounts of a compound
having anti-Xa activity and a platelet aggregation antagonist
compound. In addition, this invention is directed to the use of
pharmaceutically effective amounts of a compound having anti-Xa
activity and a platelet aggregation antagonist compound in the
preparation of a medicament for treating or preventing a
physiological condition associated with thrombosis related ischemic
disorder. Furthermore, this invention is directed to a kit for
treating or preventing a physiological condition associated with
thrombosis related ischemic disorder, said kit comprising a
plurality of separate containers, wherein at least one of said
containers contains a compound having anti-Xa activity and at least
another of said containers contains a platelet aggregation
antagonist compound, and said containers optionally contain a
pharmaceutical carrier.
Inventors: |
Uzan, Andre; (Paris, FR)
; Curaudeau, Alain H; (Devon, PA) ; Leadley,
Robert J; (Collegeville, PA) ; Dunwiddie, Christopher
T; (Carmel, IN) ; Perrone, Mark H; (Chalfont,
PA) |
Correspondence
Address: |
AVENTIS PHARMACEUTICALS, INC.
PATENTS DEPARTMENT
ROUTE 202-206, P.O. BOX 6800
BRIDGEWATER
NJ
08807-0800
US
|
Family ID: |
21861879 |
Appl. No.: |
09/516981 |
Filed: |
March 1, 2000 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09516981 |
Mar 1, 2000 |
|
|
|
09192710 |
Nov 16, 1998 |
|
|
|
6103705 |
|
|
|
|
09192710 |
Nov 16, 1998 |
|
|
|
PCT/US97/21440 |
Nov 24, 1997 |
|
|
|
60031878 |
Nov 27, 1996 |
|
|
|
Current U.S.
Class: |
514/300 |
Current CPC
Class: |
A61P 9/10 20180101; A61K
38/05 20130101; A61P 7/02 20180101; A61P 35/00 20180101; A61K 38/05
20130101; A61K 31/715 20130101; A61K 38/05 20130101; A61K 2300/00
20130101 |
Class at
Publication: |
514/300 |
International
Class: |
A61K 031/44; A01N
043/42 |
Claims
What is claimed is:
1. A pharmaceutical composition comprising a pharmaceutically
acceptable carrier and pharmaceutically effective amounts of a
compound having anti-Xa activity and a platelet aggregation
antagonist compound.
2. The pharmaceutical composition according to claim 1 wherein the
compound having anti-Xa activity is a low molecular weight
heparin.
3. The pharmaceutical composition according to claim 1 wherein the
low molecular weight heparin is selected from the group consisting
of enoxaparin, nardroparin, dalteparin, certroparin, parnaparin,
reviparin, ardeparin/RD heparin/RDH or tinzaparin.
4. The pharmaceutical composition according to claim 1 wherein the
low moleclular weight heparin is enoxaparin.
5. The pharmaceutical composition according to claim 1 wherein the
compound having anti-Xa activity is a heparinoid compound.
6. The pharmaceutical composition according to claim 1 wherein the
heparinoid compound is danaparoid.
7. The pharmaceutical composition according to claim 1 wherein the
platelet aggregation antagonist compound is abciximab,
N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-.beta.-cyc-
lohexyl alanine,
N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspart-
yl]-L-.beta.-cyclohexyl alanine amide or
N-(n-butylsulfonyl)-4-(piperidin--
4-ylbutyloxy)-L-phenylalanine
8. The pharmaceutical composition according to claim 7 wherein the
platelet aggregation antagonist compound antagonist is
abciximab.
9. The pharmaceutical composition according to claim 7 wherein the
platelet aggregation antagonist compound is
N-[N-[N-(4-(piperidin-4-yl)bu-
tanoyl)-N-ethylglycyl]aspartyl]-L-.beta.-cyclohexyl alanine.
10. The pharmaceutical composition according to claim 7 wherein the
platelet aggregation antagonist compound is
N-[N-[N-(4-(piperidin-4-yl)bu-
tanoyl)-N-ethylglycyl]aspartyl]-L-.beta.-cyclohexyl alanine
amide.
11. The pharmaceutical composition according to claim 7 wherein the
platelet aggregation antagonist compound is
N-(n-butylsulfonyl)-4-(piperi-
din-4-ylbutyloxy)-L-phenylalanine.
12. A method of treating or preventing a physiological condition
associated with a thrombosis related ischemic disorder in a patient
comprising administering to said patient pharmaceutically effective
amounts of a compound having anti-Xa activity and a platelet
aggregation antagonist compound.
13. The method of claim 12 wherein the physiological condition is
selected from stroke, atherosclerosis, anaiogenesis, thrombosis, a
thromboembolic condition, disseminated intravascular coagulation,
peripheral arterial occlusive disease, hemodialysis, an
extra-corporeal circulation requirement associated with a surgical
procedure, tissue damage caused by phospholipases A2, an acute
coronary syndrome, or a thromboembolic syndrome associated with
cancer, sepsis or obstetrical complications.
14. The method of claim 13 wherein the physiological condition is
the acute coronary syndrome.
15. The method of claim 14 wherein the acute coronary syndrome is
unstable angina or myocardial infarction.
16. The method of claim 12 wherein the treating or preventing
occurs in the course of coronary artery bypass surgery or
percutaneous transluminal coronary angioplasty.
17. The method of claim 12 wherein the treating or preventing
occurs in the course of percutaneous transluminal coronary
angioplasty. carrier.
Description
[0001] This application is a continuation application of copending
PCT US97/21440, filed Nov. 24, 1997. which designates the United
States, which, in turn, is a continuation-in-part application of
U.S. patent application Ser. No. 60/031,878, filed Nov. 27, 1996,
now abandoned.
FIELD OF THE INVENTION
[0002] This invention is directed to a pharmaceutical composition
comprising an anti-Xa activity compound and a platelet aggregation
antagonist compound which exhibits unexpectedly efficacious
activity for treating or preventing a physiological condition
associated with a thrombosis related ischemic disorder in a
patient. The invention is also directed to a method of treating or
preventing a thrombogenic condition associated with a thrombosis
related ischemic disorder in a patient comprising administering
pharmaceutically effective amounts of an anti-Xa activity compound
and a platelet aggregation antagonist compound.
[0003] Platelet fibrinogen receptor antagonists have been shown to
be effective agents for inhibiting platelet-dependent thrombus
formation in animal models of coronary thrombosis. Likewise,
results from clinical studies have shown that platelet fibrinogen
receptor antagonists reduce the composite incidence of major
ischemic events when administered to high-risk patients undergoing
percutaneous transluminal coronary angioplasty. However, the
therapeutic window is very narrow for this class of compounds, in
part, because the high degree of inhibition of ex vivo platelet
aggregation required for antithrombotic efficacy is often
associated with a marked increase in template bleeding time, which
is a marker of an undesirable bleeding complications.
[0004] Low molecular weight heparins (LMWHs) and heparinoid
compounds (HCs) have been used effectively over the past few years
for the prevention and treatment of venous thrombosis and the
associated thromboembolism. However, LMWHs and HCs are gradually
pervading into the treatment repertoire for arterial thrombotic
indications. Preliminary results favoring the use of LMWH or HCs
over unfractionated heparin in arterial thrombotic indications are
supported by several pharmacodynamic, pharmacokinetic, and
mechanistic differences between these two classes of compounds. For
example, reliable and safe anticoagulation can be achieved with
LMWHs or HCs by subcutaneous dosing without monitoring. Compared to
heparin, LMWHs and HCs have a higher bioavailability, a relatively
long half-life, and appear to have a safer profile. In addition,
LMWHs are more resistant than heparin to neutralization by platelet
factor 4, which is released from activated platelets, presumably at
the site of arterial thrombosis.
[0005] Haemostasis the biochemistry of blood coagulation, is an
extremely complex phenomena whereby normal whole blood and body
tissue spontaneously arrest bleeding from injured blood vessels.
Effective haemostasis requires the combined activity of vascular,
platelet and plasma factors as well as a controlling mechanism to
prevent excessive clotting. Defects, deficiencies, or excesses of
any of these components can lead to hemorrhagic or thrombotic
consequences.
[0006] Platelet adhesion, spreading and aggregation on
extracellular matrices are central events in thrombus formation.
These events are mediated by a family of adhesive glycoproteins,
i.e., fibrinogen, fibronectin, and von Willebrand factor.
Fibrinogen is a co-factor for platelet aggregation while
fibronectin supports platelet attachments and spreading reactions,
and von Willebrand factor is important in platelet attachment to
and spreading on subendothelial matrices. The binding sites for
fibrinogen, fibronectin and von Willebrand factor have been located
on the platelet membrane protein complex known as glycoprotein
IIb/IIIa.
[0007] Adhesive glycoproteins, like fibrinogen, do not bind with
normal resting platelets. However, when a platelet is activated
with an agonist such as thrombin or adenosine diphosphate, the
platelet changes its shape, perhaps making the GPIIb/IIIa binding
site accessible to fibrinogen. Blocking the fibrinogen receptor,
thus inhibits platelet aggregation and subsequent thrombus
formation, and is useful for the prevention and treatment of
pathological thrombogenic conditions, such as stroke, peripheral
arterial occlusive disease, disseminated intravascular coagulation,
and acute coronary syndromes such as unstable angina and myocardial
infarction.
SUMMARY OF THE INVENTION
[0008] The invention is also directed to pharmaceutical composition
comprising a compound having anti-Xa activity, a platelet
aggregation antagonist compound and a pharmaceutically acceptable
carrier. The invention is also directed to a method of treating or
preventing a thrombogenic condition associated with a thrombosis
related ischemic disorder in a patient comprising administering to
said patient pharmaceutically effective amounts of a compound
having anti-Xa activity and a platelet aggregation antagonist
compound.
BRIEF DESCRIPTION OF THE FIGURES
[0009] FIG. 1 represents information regarding assorted blood
sampling/hemodynamic measurements during administration of
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound,
N-(n-butylsulfonyl)-4-(piperidin-4-ylbut- yloxy)-L-phenylalanine
(BSPBPA), and composition thereof over time.
[0010] FIG. 2 represents a graph of the number of cyclic flow
reductions (CFRs) for different concentrations of the anti-Xa
activity compound, Enoxaparin, the platelet aggregation antagonist
compound, BSPBPA, and composition thereof over time.
[0011] FIG. 3 represents a graph of the activated partial
thromboplastin time (APTT) for different concentrations of the
anti-Xa activity compound, Enoxaparin, the platelet aggregation
antagonist compound, BSPBPA, and composition thereof over time.
[0012] FIG. 4 represents a graph of the prothrombin time (PT) for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, BSPBPA,
and composition thereof over time.
[0013] FIG. 5 represents a graph of the Anti-Xa activity for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, BSPBPA,
and composition thereof over time.
[0014] FIG. 6 represents a graph of the Anti-IIa activity for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, BSPBPA,
and composition thereof over time.
[0015] FIG. 7 represents a graph of the template bleeding time for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, BSPBPA,
and composition thereof over time.
[0016] FIG. 8 represents a graph of the platelet count for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, BSPBPA,
and composition thereof over time.
[0017] FIG. 9 represents a graph of collagen-induced ex-vivo
platelet aggregation for different concentrations of the anti-Xa
activity compound, Enoxaparin, the platelet aggregation antagonist
compound, BSPBPA, and composition thereof over time.
[0018] FIG. 10 represents a graph of ADP-induced ex-vivo platelet
aggregation for different concentrations of the anti-Xa activity
compound, Enoxaparin, the platelet aggregation antagonist compound,
BSPBPA, and composition thereof over time.
[0019] FIG. 11 represents a graph of arachidonic acid-induced
ex-vivo platelet aggregation for different concentrations of the
anti-Xa activity compound, Enoxaparin, the platelet aggregation
antagonist compound, BSPBPA, and composition thereof over time.
[0020] FIG. 12 represents a graph of thrombin-induced ex-vivo
platelet aggregation for different concentrations of the anti-Xa
activity compound, Enoxaparin, the platelet aggregation antagonist
compound, BSPBPA, and composition thereof over time.
[0021] FIG. 13 represents information regarding assorted blood
sampling/hemodynamic measurements during administration of
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound,
N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-e-
thylglycyl]aspartyl]-L-.beta.-cyclohexyl alanine amide (PBGACA) and
composition thereof over time.
[0022] FIG. 14 represents a graph of the number of cyclic flow
reductions (CFRs) for different concentrations of the anti-Xa
activity compound, Enoxaparin, the platelet aggregation antagonist
compound, PBGACA, and composition thereof over time.
[0023] FIG. 15 represents a graph of the activated partial
thromboplastin time (APTT) for different concentrations of the
anti-Xa activity compound, Enoxaparin, the platelet aggregation
antagonist compound, PBGACA, and composition thereof over time.
[0024] FIG. 16 represents a graph of the prothrombin time (PT) for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, PBGACA,
and composition thereof over time.
[0025] FIG. 17 represents a graph of the Anti-Xa activity for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, PBGACA,
and composition thereof over time.
[0026] FIG. 18 represents a graph of the Anti-IIa activity for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, PBGACA,
and composition thereof over time.
[0027] FIG. 19 represents a graph of the template bleeding time for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound. PBGACA,
and composition thereof over time.
[0028] FIG. 20 represents a graph of the platelet count for
different concentrations of the anti-Xa activity compound,
Enoxaparin, the platelet aggregation antagonist compound, PBGACA,
and composition thereof over time.
[0029] FIG. 21 represents a graph of collagen-induced ex-vivo
platelet aggregation for different concentrations of the anti-Xa
activity compound, Enoxaparin, the platelet aggregation antagonist
compound, PBGACA, and composition thereof over time.
[0030] FIG. 22 represents a graph of ADP-induced ex-vivo platelet
aggregation for different concentrations of the anti-Xa activity
compound, Enoxaparin, the platelet aggregation antagonist compound,
PBGACA, and composition thereof over time.
[0031] FIG. 23 represents a graph of arachidonic acid-induced
ex-vivo platelet aggregation for different concentrations of the
anti-Xa activity compound, Enoxaparin, the platelet aggregation
antagonist compound, PBGACA, and composition thereof over time.
[0032] FIG. 24 represents a graph of thrombin-induced ex-vivo
platelet aggregation for different concentrations of the anti-Xa
activity compound, Enoxaparin, the platelet aggregation antagonist
compound, PBGACA, and composition thereof over time.
DETAILED DESCRIPTION OF THE INVENTION
[0033] As used above, and throughout the description of the
invention, the following terms, unless otherwise indicated, shall
be understood to have the following meanings:
[0034] Definitions
[0035] "Patient" includes both human and other mammals.
[0036] "Effective amount" is meant to describe an amount of
composition according to the present invention effective in
producing the desired therapeutic effect.
[0037] "Platelet aggregation antagonist compound" (PAAC) means a
compound that binds to the platelet GPIIb/IIIa receptor (GPIIb/IIIa
receptor antagonist) and competitively inhibits binding of
fibrinogen, fibronectin and von Willebrand factor as well as
inhibits aggregation of activated platelets.
[0038] "Anti-Xa activity compound" means a heparinoid compound or
low molecular weight heparin (LMWH), or synthetic derivatives
thereof.
[0039] Preferred Embodiments
[0040] According to a preferred embodiment of the invention, the
following references, incorporated herein by reference, describes
useful PAACs: Lynch et al. J. Pharm. Expt. Thera. 272(1) 20 (1995);
Kereiakes et al. JACC 27(3), 536 (1996); Peerlinck et al.
Circulation 88(4), 1512 (1993); Barrett et al. Clin. Pharmacol.
Ther. 56(4) 377 (1994); Cook et al. Thromb. Haemostas. 70(5), 838
(1993): Plow, et al.. Proc. Natl. Acad. Sci. USA 82, 8057-61
(1985); Ruggeri, et al., Proc. Natl. Acad. Sci. USA 5708-12 (1986);
Ginsberg, et al., J. Biol. Chem. 260, 3931-36 (1985); and Gartner,
et al., J. Biol. Chem. 260, 11,891-94 (1987); Plow, E. F., et al.,
Proc. Natl. Acad. Sci. USA 79, 3711-3715 (1982); Tjoeng. et al.,
U.S. Pat. Nos. 5,037,808, 4,879,313 and 4,992,463; Adams, et al.,
U.S. Pat. No. 4,857,508; Haverstick, D. M., et al., Blood 66(4),
946-952 (1985): Topol et al.. The Lancet, 343, 881 (1994), French
Application No. 86/17507; Zimmerman, et al., U.S. Pat. No.
4,683,291; European Application Publication No. 0 319 506; U.S.
Pat. No. 5,023,233; U.S. Pat. No. 4,952.562; International
Publication No. WO 91/04746; U.S. application Ser. No. 5,086,069;
International Publication No. WO 92/13117; U.S. Pat. No. 5,053,392;
U.S. Pat. No. 5,064,814; U.S. Pat. No. 5,051,405; European Patent
Application 0479,481; European Patent Application 0478,362; U.S.
Pat. No. 5,292,756; International Publication No. WO 95/10295; and
International Publication No. WO 89/11538. More preferred PAACs are
those disclosed in International Publication No. WO 89/11538,
International Publication No. WO 95/10295 or U.S. Pat. No.
5,292,756; further preferred are Reopro.RTM. (abciximab).
N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]asparty]-L-.beta.-cycl-
ohexyl alanine,
N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]-L-.bet-
a.-cyclohexyl alanine amide (PBGACA) or
N-(n-butylsulfonyl)-4-(piperidin-4- -ylbutyloxy)-L-phenylalanine
(BSPBPA).
[0041] According to a preferred embodiment of the invention, the
following references, incorporated herein by reference, describes
useful LMWHs according to the invention and methods for preparing
the LMWHs: Eur. Pat. No. 0014184; Medicinal Research Reviews 12(4),
373 (1992); Drugs of the Future 12(1), 45 (1987); International
Publication No. WO 92/19249; U.S. Pat. No. 4,692,435; Barrowcliffe,
Thromb. Res. 12, 27-36 (1977); Eur. Pat. Appln. No. 37319; Eur.
Pat. Appln. No. 76279; U.S. Pat. No. 4,804,652; WO81/3276; Eur.
Pat. Appln. No. 244235, Eur. Pat. Appln. No. 244236; U.S. Pat. No.
4,486,420; U.S. Pat. No. 4,692,435; U.S. Pat. No. 4,826,827; U.S.
Pat. No. 3,766,167; Eur. Pat. Appln. No. 40144; Eur. Pat. Appln.
No.347588, Eur. Pat. Appln. No. 380943; U.S. Pat. No. 4,533,549;
U.S. Pat. No. 4,629,699; Eur. Pat. Appln. No. 269981. For example,
an anti-Xa activity compound may be produced as follows: enrichment
by fractionation by ethanol and/or molecular sieving. e.g., gel
filtration or membrane filtration of the LMWH present in standard
heparin and controlled chemical (by nitrous acid,
.beta.-elimination or periodate oxidation) or enzymatic (by
heparinases) depolymerization. The conditions for depolymerization
can be carefully controlled to yield products of desired molecular
weights. Nitrous acid depolymerization is commonly used. Also
employed is depolymerization of the benzylic ester of heparin by
.beta.-elimination, which yields the same type of fragments as
enzymatic depolymerization using heparinases. LMWH with low
anticoagulant activity and retaining basic chemical structure are
prepared by depolymerization using periodate oxidation or by
removing the antithrombin-binding fraction of LMWH, or prepared by
other methods, using immobilized antithrombin for adsorption.
[0042] Further preferred is a LMWH having an average molecular
weight of about 3000 to about 6500. Commercially available LMWHs
useful according to the invention include the following:
Clexane.RTM./Klexane.RTM./Lovenox- .RTM. (Enoxaparin (ENOX)) having
an average molecular mass of 4500.+-.1000 Dalton (Da), molecular
mass distribution comprising components of <2000 Da
(16.0.+-.4.0%) and 2000 to 8000 Da (78.0.+-.10.0%). Anti-Xa
activity (IU/mg on dry basis) of 90 to 125, and an Anti-Xa/Anti-IIa
ratio of 3.3 to 5.3; Fraxiparin.RTM. (Nardroparin) having an
average molecular mass of 4300.+-.700 Da, molecular mass
distribution comprising components of <2000 Da (<15%), 2000
to 4000 Da (45.+-.10%) and 2000 to 8000 Da (85.+-.10%), Anti-Xa
activity (IU/mg on dry basis) of 95 to 130, and an Anti-Xa/Anti-IIa
ratio of 2.5 to 4.0; Fragmin.RTM. (Dalteparin) having an average
molecular mass of 6000.+-.400 Da. molecular mass distribution
comprising components of <3000 Da (5.0 to 13.0%) and >8000 Da
(15.0 to 25.0%). Anti-Xa activity (IU/mg on dry basis) of 110 to
210, and an Anti-Xa/Anti-IIa ratio of 1.9 to 3.2;
Embolex.RTM./Monoembolex.RTM. (Certroparin) having an average
molecular mass of 5200.+-.1000 Da, molecular mass distribution
comprising components of <2000 Da (10 to 25%) and <8000 Da
(75 to 90%), Anti-Xa activity (IU/mg on dry basis) of 80 to 120,
and an Anti-Xa/Anti-IIa ratio of 1.5 to 2.5;
Fluxum.RTM./Minidalton.RTM./Lowhepa.RTM. (Parnaparin) having an
average molecular mass of 5000.+-.1000 Da, molecular mass
distribution comprising components of <3000 Da (20 to 30%) and
3000 to 8000 Da (50 to 60%), Anti-Xa activity (IU/mg on dry basis)
of 75 to 110, and an Anti-Xa/Anti-IIa ratio of 2.0 to 3.0;
Logiparin.RTM. (Tinzaparin) having an average molecular mass of
3400 to 5600 Da, molecular mass distribution comprising components
of <2000 Da (2.0 to 16.0%), 2000 to 4000 Da (66.0.+-.6.0%) and
>8000 Da (12.0 to 38.0%), Anti-Xa activity (IU/mg on dry basis)
of>70, and an Anti-Xa/Anti-IIa ratio of 1.5 to 2.5;
Clivarine.RTM. (Reviparin) and Normiflo.RTM. (ardeparin/RD
heparin/RDH). A preferred LMWH according to the invention is
prepared according to the procedures disclosed in U.S. Pat. No.
4,486,420 or U.S. Pat. No. 4,692,435; more preferred
enoxaparin.
[0043] According to another preferred embodiment of the invention,
an anti-Xa activity compound is a heparinoid compound. The
following references, incorporated herein by reference, describe a
useful heparinoid compound according to the invention and methods
for preparing the heparinoid compound: U.S. Pat. No. 4,438,108,
Eur. Pat. No. EP 66908, Zammit et al. Thromb. Haemostas. 71(6), 759
(1994), and Gent et al. Circulation 93, 80 (1996). A preferred
commercially available heparinoid compound useful according to the
invention is Orgaran.RTM. (Danaparoid) having an average molecular
mass of about 6500 Da, Anti-Xa activity (IU/mg on dry basis) of
about 10, and an Anti-Xa/Anti-IIa ratio of about 28.
[0044] Preferred thrombogenic conditions treatable or preventable
according to the invention include stroke, atherosclerosis,
angiogenesis, thrombosis, thromboembolic conditions such as deep
venous thrombosis. pulmonary embolism or thrombophlebitis,
disseminated intravascular coagulation or thromboembolic syndromes
associated with cancer, sepsis or obstetrical complications,
peripheral arterial occlusive disease, and acute coronary syndromes
such as unstable angina and myocardial infarction. hemodialysis, or
extra-corporeal circulation requirement associated with a surgical
procedure or tissue damage caused by phospholipases A2 (PLA.sub.2),
more preferred is unstable angina and myocardial infarction.
[0045] Another preferred embodiment according to the invention
useful in the course of a medical procedure wherein there is a
potential for an occurrence pathological thrombogenic condition may
occur, such as during coronary artery bypass surgery or
percutaneous transluminal coronary angioplasty with or without
placement of an intracoronary stent; more preferred is percutaneous
transluminal coronary angioplasty with or without placement of an
intracoronary stent.
[0046] Another preferred embodiment according to the invention is
the use of pharmaceutically effective amounts of a compound having
anti-Xa activity and a platelet aggregation antagonist compound in
the preparation of a medicament for treating or preventing a
physiological condition associated with thrombosis related ischemic
disorder.
[0047] In the treatment or prevention method according to the
invention the anti-Xa activity compound and platelet aggregation
antagonist compound may be administered in different ways, such as
in combination therapies optionally employing medical procedures.
For example, the anti-Xa activity compound and platelet aggregation
antagonist compound may be administered to a patient concomitantly
or at different times provided that they are administered such that
at some period of time there are pharmaceutically effective amounts
of both compounds present in the patient such that a therapeutic
effect according to the invention results.
[0048] Thus, it is a further object of the invention to provide a
kit for treating or preventing a physiological condition associated
with thrombosis related ischemic disorder, said kit comprising a
plurality of separate containers, wherein at least one of said
containers contains a compound having anti-Xa activity and at least
another of said containers contains a platelet aggregation
antagonist compound, and said containers optionally contain a
pharmaceutical carrier which kit may be effectively utilized for
carrying out combination therapies according to the invention. A
further embodiment for a kit would be wherein of said containers at
least one of said containers should contain the compound having
anti-Xa activity without the presence of the platelet aggregation
antagonist compound, and at least another of said containers should
contain the platelet aggregation antagonist compound without the
presence of the compound having anti-Xa activity.
[0049] In practice, the anti-Xa activity compound and platelet
aggregation antagonist compound may be administered parenterally,
topically, rectally, transdermally, intrapulmonary or orally, but
they are preferably administered parenterally and/or orally.
[0050] Suitable compositions containing the compounds used
according to the invention may be prepared by conventional means.
For example, the compounds used according to the invention may be
dissolved or suspended in a suitable carrier.
[0051] The compounds used according to the invention should be
presented in forms permitting administration by the most suitable
route, and the invention also relates to a pharmaceutical
composition containing the compounds used according to the
invention which are suitable for use in human or veterinary
medicine. These compositions may be prepared according to the
customary methods, using one or more pharmaceutically acceptable
carrier, which comprise adjuvants or excipients. The adjuvants
comprise, inter alia, diluents, sterile aqueous media and the
various non-toxic organic solvents. The compositions may be
presented in the form of tablets, pills, capsules, lozenges,
troches, hard candies, granules, powders, aqueous solutions or
suspensions, injectable solutions, elixirs or syrups, powders,
solution or suspension for intrapulmonary administration and can
contain one or more agents chosen from the group comprising
sweeteners, flavorings, colorings, or stabilizers in order to
obtain pharmaceutically acceptable preparations.
[0052] The choice of vehicle and the content of compounds used
according to the invention in the vehicle are generally determined
in accordance with the solubility and chemical properties of the
compounds, the particular mode of administration and the provisions
to be observed in pharmaceutical practice. For example, excipients
such as sterile water, Ringer's solution, lactose, sodium citrate,
isotonic saline solutions (monosodium or disodium phosphate,
sodium, potassium, calcium or magnesium chloride, or mixtures of
such salts), calcium carbonate and disintegrating agents such as
starch, alginic acids and certain complex silicates combined with
lubricants such as magnesium stearate, sodium lauryl sulfate and
talc may be used for preparing tablets. To prepare a capsule, it is
advantageous to use lactose and high molecular weight polyethylene
glycols. When aqueous suspensions are used they can contain
emulsifying agents or agents which facilitate suspension. Diluents
such as sucrose, ethanol, polyethylene glycol, propylene glycol,
glycerol and chloroform or mixtures thereof may also be used.
[0053] For parenteral administration, emulsions, suspensions or
solutions of the compounds used according to the invention in
vegetable oil, for example sesame oil, groundnut oil or olive oil,
or aqueous-organic solutions such as water and propylene glycol,
injectable organic esters such as ethyl oleate, as well as sterile
aqueous solutions of the pharmaceutically acceptable salts, are
useful. The solutions of the salts of the compounds used according
to the invention are especially useful for administration by
intramuscular, intravenous, intraarterial or subcutaneous injection
or infusion techniques. The aqueous solutions, also comprising
solutions of the salts in pure distilled water, may be used for
intravenous administration with the proviso that their pH is
suitably adjusted, that they are judiciously buffered and rendered
isotonic with a sufficient quantity of glucose or sodium chloride
and that they are sterilized by heating, irradiation or
microfiltration.
[0054] The anti-Xa activity compound and platelet aggregation
antagonist compound according to the invention may also be
formulated in a manner which resists rapid clearance from the
vascular (arterial or venous) wall by convection and/or diffusion,
thereby increasing the residence time of the composition at the
desired site of action. Depot useful according to the invention may
be in a copolymer matrix, such as ethylene-vinyl acetate, or a
polyvinyl alcohol gel surrounded by a Silastic shell.
Alternatively, the anti-Xa activity compound and platelet
aggregation antagonist compound may be delivered locally from a
silicone polymer implanted in the adventitia.
[0055] An alternative approach for minimizing washout of the
anti-Xa activity compound and platelet aggregation antagonist
compound during percutaneous, transvascular delivery comprises the
use of nondiffusible, drug-eluting microparticles. The
microparticles may be comprised of a variety of synthetic polymers,
such as polylactide for example, or natural substances, including
proteins or polysaccharides. Such microparticles enable strategic
manipulation of variables including total dose of a drug and
kinetics of its release. Microparticles can be injected efficiently
into the arterial or venous wall through a porous balloon catheter
or a balloon over stent, and are retained in the vascular wall and
the periadventitial tissue for at least about two weeks.
Formulations and methodologies for local, intravascular
site-specific delivery of therapeutic agents are discussed in
Reissen et al. (J. Am. Coll. Cardiol. 1994; 23: 1234-1244), the
entire contents of which are hereby incorporated by reference.
[0056] The medium for the anti-Xa activity compound and platelet
aggregation antagonist compound can also be a hydrogel which is
prepared from any biocompatible or non-cytotoxic (homo or hetero)
polymer, such as a hydrophilic polyacrylic acid polymer that can
act as a drug absorbing sponge. Such polymers have been described,
for example, in application WO93/08845. the entire contents of
which are hereby incorporated by reference. Certain of them, such
as, in particular, those obtained from ethylene and/or propylene
oxide are commercially available.
[0057] In addition, the anti-Xa activity compound and platelet
aggregation antagonist compound may be administered directly to the
blood vessel wall by means of an angioplasty balloon which is
coated with a hydrophilic film (for example a hydrogel), or by
means of any other catheter containing an infusion chamber for the
compounds, which can thus be applied in a precise manner to the
site to be treated.
[0058] The percentage of the anti-Xa activity compound and platelet
aggregation antagonist compound used according to the invention may
be varied. The compounds should constitute a proportion such that a
suitable dosage shall be obtained. Obviously, several unit dosage
forms may be administered. The dose employed will be determined by
the physician, and depends upon the desired therapeutic effect, the
route of administration and the duration of the treatment, and the
condition of the patient. In each particular case, the doses will
be determined in accordance with the factors distinctive to the
subject to be treated, such as age, weight, general state of health
and other characteristics which can influence the efficacy of the
medicinal product.
[0059] In the adult, the dosages of the PAAC are generally from
about 0.0001 to about 50, preferably about 0.0001 to about 5, mg/kg
body weight per day by inhalation, from about 0.001 to about 100,
preferably 0.01 to 70, more especially 0.05 to 10, mg/kg body
weight per day by oral administration, and from about 0.0001 to
about 10, preferably 0.001 to 1, mg/kg body weight per day by
intravenous administration.
[0060] In the adult, the dosages of the anti-Xa activity compound
according to the invention is particularly useful in doses of about
10 to about 25,000 international units of anti-Xa activity.
[0061] The anti-Xa activity compound and platelet aggregation
antagonist compound used according to the invention may be
administered as frequently as necessary in order to obtain the
desired therapeutic effect. The dosage regimen in carrying out the
method of this invention is that which insures maximum therapeutic
response until improvement is obtained and thereafter the minimum
effective level which gives relief. Some patients may respond
rapidly to a higher or lower dose and may find much weaker
maintenance doses adequate. Both short- and long-term treatments
regimens are contemplated for the invention. Treatments at the rate
of about 1 to about 4 doses per day are also contemplated, in
accordance with the physiological requirements of each particular
patient, bearing in mind of course, that in selecting the
appropriate dosages in any specific case, consideration must be
given to the patient's weight, general health, age, and other
factors which may influence response to the drug. Thus, for other
patients, it will be necessary to prescribe not more than one or
two doses per day.
[0062] The compounds of the present invention may also be
formulated for use in conjunction with other therapeutic agents
such as agents or in connection with the application of therapeutic
techniques to address pharmacological conditions which may be
ameliorated through the application of a compound of formula I,
such as in the following:
[0063] The compounds of the present invention may be used in the
treatment of restenosis post angioplasty using any device such as
balloon, ablation or laser techniques. The compounds of the present
invention may be used in the treatment of restenosis following
stent placement in the vasculature either as 1) primary treatment
for vascular blockage, or 2) in the instance where angioplasty
using any device fails to give a patent artery. The compounds of
the present invention may be used either orally, by parenteral
administration or the compound could be applied topically through
the intervention of a specific device or as a properly formulated
coating on a stent device.
[0064] The compounds of the present invention may be used in the
treatment of restenosis in combination with any anticoagulant,
antiplatelet, antithrombotic or profibrinolytic agent. Often
patients are concurrently treated prior, during and after
interventional procedures with agents of these classes either in
order to safely perform the interventional procedure or to prevent
deleterious effects of thrombus formation. Some examples of classes
of agents known to be anticoagulant, antiplatelet, antithrombotic
or profibrinolytic agents include any formulation of thrombin
inhibitors or Factor VIIa inhibitors. Some examples of classes of
agents known to be anticoagulant, antiplatelet, antithrombotic or
profibrinolytic agents include any formulation of aspirin, direct
thrombin inhibitors, direct Factor Xa inhibitors, or Factor VIIa
inhibitors.
[0065] The compounds of the present invention may be used in
combination with any antihypertensive agent or cholesterol or lipid
regulating agent in the treatment of restenosis or atherosclerosis
concurrently with the treatment of high blood pressure or
atherosclerosis. Some examples of agents that are useful in the
treatment of high blood pressure include compounds of the following
classes; beta-blockers, ACE inhibitors, calcium channel antagonists
and alpha-receptor antagonists. Some examples of agents that are
useful in the treatment of elevated cholesterol levels or
disregulated lipid levels include compounds known to be HMGCoA
reductase inhibitors, compounds of the fibrate class,
[0066] The anti-Xa activity compound and platelet aggregation
antagonist compound used according to the invention exhibit marked
pharmacological activities according to tests described in the
literature which tests results are believed to correlate to
pharmacological activity in humans and other mammals. The following
pharmacological test results are typical characteristics of the
anti-Xa activity compound and platelet aggregation antagonist
compound used according to the invention.
[0067] The following pharmacological tests evaluate the activity of
anti-Xa activity compound and platelet aggregation antagonist
compound used according to the invention. Those tests include the
hemodynamics measurements during administration of different
concentrations of an anti-Xa activity compound, a platelet
aggregation antagonist compound and composition thereof over time
(FIGS. 1 and 13). More specifically measurements were taken of
cyclic flow reduction (FIGS. 2 and 14), activated partial
thromboplastin time (FIGS. 3 and 15), prothrombin time (FIGS. 4 and
16), Anti-Xa activity (FIGS. 5 and 17), Anti-IIa activity (FIGS. 6
and 18), template bleeding time (FIGS. 7 and 19). platelet count
(FIGS. 8 and 20), collagen-induced ex-vivo platelet aggregation
(FIGS. 9 and 21), ADP-induced ex-vivo platelet aggregation (FIGS.
10 and 22), arachidonic acid-induced ex-vivo platelet aggregation
(FIGS. 11 and 23), and thrombin-induced ex-vivo platelet
aggregation (FIGS. 12 and 24).
[0068] Compositions of the present invention exhibit marked
activity in the foregoing tests and are considered useful in the
prevention and treatment of thrombosis associated with certain
disease states. Antithrombotic activity in the ex vivo canine
platelet aggregation assay is predictive of such activity in humans
(see, for example Catalfamo, J. L., and Dodds, W. Jean, "Isolation
of Platelets from Laboratory Animals", Methods Enzymol. 169, Part
A, 27 (1989)).
Materials and Methods
[0069] All procedures in this study are performed in compliance
with the Animal Welfare Act Regulations and with the Guide for the
Care and Use of Laboratory Animals (DHEW Publication No. NIH 85-23,
1985).
[0070] The test protocol as follows is an experimental model of
unstable angina.
[0071] Mongrel dogs of either sex (15-21 kg) are anesthetized with
sodium pentobarbital (30 mg/kg, i.v., with supplements given as
needed), intubated, and ventilated using a Harvard respirator
(Harvard Apparatus. S. Natick, Mass.). A tri-lumen catheter
(SAFEDWELLplus, Becton Dickinson, Sandy, Utah) is placed in the
right femoral vein for the administration of test agents and
supplemental anesthesia. The right femoral artery is cannulated for
measurement of arterial blood pressure and for obtaining blood
samples.
[0072] A left thoracotomy is performed at the 5th intercostal space
and the heart is suspended in a pericardial cradle. The left
circumflex coronary artery (LCX) is isolated and dissected for a
distance of 2 cm, ligating side branches when necessary. An
electromagnetic flow probe (Carolina Medical Electronics, 501D) is
placed on the vessel to monitor coronary blood flow and a snare
ligature is placed on the distal portion of the vessel to produce a
temporary mechanical occlusion which is used to aid in adjusting
the degree of stenosis and to aid in validating zero flow
measurements.
[0073] Distal to the flow probe, a Lexan.RTM. occluder is
positioned for the purpose of creating a critical stenosis, which
is confirmed by abolishment of the hyperemic response to a 10 sec
mechanical occlusion of the vessel. The endothelium and vascular
smooth muscle cells are damaged by compressing the vessel with a
vascular clamp. These conditions result in platelet adhesion and
aggregation at the damaged area, thus producing a gradual decrease
in coronary blood flow. When flow reaches zero, the occluder is
moved back and forth over the damaged area to mechanically dislodge
the platelet-rich thrombus, thus restoring blood flow. This
repetitive pattern of decreasing blood flow that is restored by
mechanical disruption of the platelet thrombus is referred to as
cyclic flow reductions (CFRs). The antithrombotic effect of the
test agents is quantitated by comparing the number of CFRs that
occurred during a 20 min control period with the number of CFRs per
20 min for three consecutive 20 min periods after drug
administration. A significant reduction in the number of CFRs is
taken to represent an antithrombotic effect.
[0074] Experimental Protocol
[0075] a. Protocol using BSPBPA
[0076] Thirty dogs are assigned to one of six adjunctive treatment
groups. The compounds are administered as an intravenous bolus only
(for N-(n-butylsulfonyl)-4-(piperidin-4-ylbutyloxy)-L-phenylalanine
(BSPBPA) or saline vehicle) or as an intravenous bolus plus a
constant intravenous infusion (for heparin, enoxaparin (ENOX), or
saline vehicle. The treatment groups are: I) BSPBPA (30 .mu.g/kg),
II) BSPBPA (300 .mu.g/kg), III) ENOX (0.5 mg/kg+5 .mu.g/kg/min) IV)
ENOX (0.5 mg/kg+5 .mu.g/kg/min) plus BSPBPA (30 .mu.g/kg), V)
heparin (60 U/kg+0.7 U/kg/min), and VI) heparin (60 U/kg+0.7
U/kg/min) plus BSPBPA (30 .mu.g/kg). All compounds are diluted in
saline and bolus injections are made using a volume of 5 mL and
constant infusions are made using a volume of 22 mL.
[0077] a. Protocol using PBGACA
[0078] Thirty dogs are assigned to one of six adjunctive treatment
groups. The compounds for these experiments involves the
administration of the following agents as a bolus and a constant
infusion (for
N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-.beta.-cyc-
lohexyl alanine amide (PBGACA) or saline vehicle) or as an
intravenous bolus plus a constant intravenous infusion (for
heparin, ENOX, or saline vehicle. The treatment groups were: I)
PBGACA (10 .mu.g/kg+0.15 .mu.g/kg/min). II) PBGACA (30
.mu.g/kg+0.15 .mu.g/kg/min), III) ENOX (0.5 mg/kg+5 .mu.g/kg/min)
IV) ENOX (0.5 mg/kg+5 .mu.g/kg/min) plus PBGACA (10 .mu.g/kg+0.15
.mu.g/kg/min), V) heparin (60 U/kg+0.7 U/kg/min), and VI) heparin
(60 U/kg+PBGACA (10 .mu.g/kg+0.15 .mu.g/kg/min),. All compounds are
diluted in saline and bolus injections are made using a volume of 5
mL and constant infusions were made using a volume of 22 mL.
[0079] After consistent CFRs are established for at least 20
minutes, compounds are administered as described above and blood
flow is monitored during the one hour infusion period. Arterial
blood samples are drawn before administration of test agents
(control sample) and at 5, 10, 30, and 60 min after administration
of compounds. Blood samples are drawn on {fraction (1/10)} volume
of 3.8% trisodium citrate and are used for ex vivo platelet
aggregation, platelet count, anti-Xa levels, anti-IIa levels, and
coagulation time assays (activated partial thromboplastin time,
APTT, and prothrombin time, PT). Blood samples (4.5 mL) obtained
for analysis of anti-Xa and anti-IIa levels are collected in
chilled syringes containing 0.5 mL trisodium citrate and
immediately placed on ice. Mean arterial blood pressure, heart rate
and EKG are recorded for the duration of the protocol (Grass
polygraph, Model 7D, Grass Instruments, Mass.).
[0080] Coagulation times and template bleeding time. Activated
partial thromboplastin time (APTT) and prothrombin time (PT) are
measured using a Microsample Coagulation Analyzer (MCA210, Bio Data
Corp, Horsham, Pa.) and Dade.RTM. reagents (Thromboplastin-C Plus
and Actin.RTM. FS Activated PTT reagent, Baxter Diagnostics, Inc.,
Deerfield. Ill.).
[0081] The APTT is the most widely used method for monitoring
intravenous heparin anticoagulation therapy. It is also a
fundamental screening test for deficiencies or abnormalities of the
intrinsic coagulation factors: VIII, IX, XI, XII, and factors
common to both the intrinsic and extrinsic pathways: I
(fibrinogen), II, V, X. When used in conjunction with deficient
substrate plasma, the APTT provides the basis for the quantitation
of specific coagulation factors.
[0082] The intrinsic capability of blood to form a fibrin clot
requires coagulation factors XII, XI, IX, VIII, X, V, II
(prothrombin), fibrinogen, platelet lipid, and calcium.
[0083] By adding a substance to activate factors XII and XI, the
contact factors, the partial thromboplastin time becomes the
"activated" partial thromboplastin time (APTT). Because coagulation
endpoints are shorter and sharper than with the PTT, the APTT has
proven to be a simple and highly reliable measurement of the
intrinsic coagulation mechanism.
TEST PROCEDURE
[0084] 1. Preincubate 0.025 M Calcium Chloride to 37.degree. C.
[0085] 2. Pipette 0.1 mL of reconstituted APTT reagent into a test
cuvette.
[0086] 3. Add 0.1 mL test or control plasma.
[0087] 4. Incubate at 37.degree. C. for 5 minutes exactly.
[0088] 5. Add 0.1 mL preincubated Calcium Chloride, simultaneously
starting the timer.
[0089] 6. Record the clotting time.
[0090] The prothrombin time is the method for monitoring oral
anticoagulation therapy. It is also a fundamental screening test
for a deficiency or abnormality of extrinsic coagulation factor
VII, and the factors common to both the intrinsic and extrinsic
hemostatic pathways: fibrinogen II, V and X. When used in
conjunction with deficient substrate plasma, the PT provides the
basis for the quantification of specific coagulation factors.
[0091] The capability of blood to form a fibrin clot by way of the
extrinsic hemostatic pathway requires tissue thromboplastin,
calcium, factor VII, factor V, factor X, factor II (prothrombin)
and factor I (fibrinogen). When tissue thromboplastin and calcium
are added to a sample of citrated plasma the actions of the
intrinsic factors are bypassed and the reaction becomes specific
for the coagulation factors involved in the extrinsic and common
pathways.
[0092] TEST PROCEDURE
[0093] 1. Preincubate reconstituted PT reagent to 37.degree. C.
[0094] 2. Pipette 0.1 mL of test or control plasma into a test
cuvette.
[0095] 3. Incubate at 37.degree. C. for at least 2 minutes, but not
more than 10 minutes.
[0096] 4. Inject 0.2 mL of the preincubated reagent, simultaneously
starting the timer.
[0097] 5. Record the clotting time.
[0098] Template bleeding time measurements are obtained at the same
time points as the blood samples, as mentioned previously. Template
bleeding time is measured after a uniform incision is made on the
mucous membrane of the inner upper lip with a Surgicutt.RTM.
automated incision device (ITC, Edison, N.J.). Blood is blotted
with Surgicutt.RTM. bleeding time blotting paper every 30 seconds,
being careful not to disturb the incision site. Template bleeding
time is measured from the moment of the incision until the blood no
longer stained the blotting paper. Bleeding times of 10 minutes are
taken to be maximal.
[0099] Anti-Xa and anti-IIa activity
[0100] These samples are centrifuiged at 1500 x g for 10 min at
4.degree. C. The plasma is removed and stored at -70.degree. C.
until assayed. Anti-Xa and Anti-IIa activity are analyzed by
chromogenic methods using kits supplied by American Diagnostica
(actichrome.RTM. Heparin and actichrome.RTM. Heparin anti-IIa,
Greenwich, Conn.), with minor modifications. Incubations and
reactions are performed at 37.degree. C. Amidolytic activity
(milli-optical units, or mOD) is determined using a SPECTRAmax
microtiter plate spectrophotometer and Softmax Pro software
(Molecular Devices Corp., Sunnyvale, Calif.). The 1st International
LMWH Standard (National Institute for Biological Standards and
Control, London; anti-Xa activity 168 IU/mg and anti-IIa activity
66.5 IU/mg) is used to construct standard curves for measuring
heparin and ENOX anti-Xa and anti-IIa activity. The curves are
constructed using a four parameter curve-fitting model (Softmax
Pro, Molecular Devices, Sunnyvale, Calif.). Values for anti-Xa and
anti-IIa activity of heparin and ENOX are reported in International
Units.
[0101] Platelet aggregation
[0102] The Inhibition of ex-vivo Platelet Aggregation assay is
based on that of Zucker, "Platelet Aggregation Measured by the
Photoelectric Method", Methods in Enzymology 169, 117-133
(1989).
[0103] Platelet rich plasma (PRP) is prepared by centrifugation of
the blood samples at 150 x g for 10 min. After removal of the
supernatant containing PRP, platelet-poor plasma (PPP) is prepared
by centrifugation of the remaining sample at 1000 x g for 10 min.
Platelet count is determined with a Coulter ZM or Coulter ZBI
particle counter (Coulter Instruments, Hialeah, Fla.). When
necessary, platelet count is adjusted to 3.times.10.sup.8
platelets/mL using autologous PPP. PRP (250 .mu.L) is incubated at
37.degree. C. while being stirred at 1200 rpm. After preincubation
with epinephrine for 1 min (1 .mu.M. Chrono-par 393, Chrono-log
Corp., Havertown, Pa.), platelet aggregation is induced by
adenosine diphosphate (ADP, 10 .mu.M, Chrono-par 384, Chrono-log
Corp. Havertown, Pa.), collagen (equine tendon, 10 .mu.g/mL,
Chrono-par 385, Chrono-log Corp., Havertown, Pa.), arachidonic acid
(1 mM, Biodata Corp, Horsham, Pa.) or thrombin (4 Units/mL, Enzyme
Research Institute, South Bend, Ind.; plus Gly-Pro-Arg-Pro, a
fibrin polymerization inhibitor, 2 mM, Sigma Chemical Co., St.
Louis, Mo.). Platelet aggregation is monitored
spectrophotometrically with a PAP-4C platelet aggregator (Bio Data
Corp, Horsham. Pa.). Results are expressed as a percent inhibition
of the rate of aggregation as compared to the pre-drug aggregation
response.
[0104] Statistics
[0105] Data obtained by multiple sampling during the experiment are
analyzed by two-way repeated measures analysis of variance.
Post-hoc multiple comparisons of means to control values within
treatment groups, and comparison of ENOX data to other treatment
groups, are performed using the least significant difference test.
A p-value less than 0.05 is considered significant.
[0106] Results
[0107] The combined use of an anti-Xa activity compound and a
platelet aggregation antagonist compound used according to the
invention, provides for use of those compounds at doses that would
be subefficacious if used individually, while effecting the
inhibition of repetitive platelet thrombus formation to the same
extent as high doses of the platelet aggregation antagonist
compound without significantly increasing template bleeding time
(as compared to: a >5-fold increase in template bleeding time
caused by high-dose of the platelet aggregation antagonist
compound, BSPBPA; and a .about.3-fold increase in template bleeding
time caused by high-dose of the platelet aggregation antagonist
compound, PBGACA).
[0108] Combination of a low-dose of a platelet aggregation
antagonist compound with heparin, at a dose which increased APTT
2.0- to 2.5- fold over baseline, did not inhibit repetitive
platelet thrombus formation.
[0109] The present invention may be embodied in other specific
forms without departing from the spirit or essential attributes
thereof.
* * * * *